<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702659</url>
  </required_header>
  <id_info>
    <org_study_id>2020-10-002B</org_study_id>
    <nct_id>NCT04702659</nct_id>
  </id_info>
  <brief_title>Chinese Medicine Zhengyi Prescription Tea Bag</brief_title>
  <official_title>The Study of Clinical Observation About Chinese Medicine Zhengyi Prescription</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chinese herbal tea bags can adjust physiological functions, help protect power, and give&#xD;
      positive energy to the body. This prescription not only focuses on regulating the patient's&#xD;
      physical function, but also helps to enhance physical strength.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Taiwan ,acoording to the TCM theories and viewpoints, Chinese herbal medicine plays an&#xD;
      important role in clinical drug application.TCM compound combinations for different diseases,&#xD;
      emphasizing the complementarity and balance of ingredients, natural gentleness, uniqueness&#xD;
      and efficacy are widely accepted by the public.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>questionnaire-the Chinese Version of the 31-Item Rhinosinusitis Outcome Measure</measure>
    <time_frame>28days</time_frame>
    <description>The questionnaire contains a total of 31 assessment items:&#xD;
Divided into 7 major aspects: nasal symptoms (6 questions), eye symptoms (2 questions), Sleep condition (4 questions), ear symptoms (5 questions), overall symptoms (7 questions), daily life Influence (4 questions) and the influence of emotions (3 questions). According to the patient's four weeks,the symptoms within are scored for each item, and the first category is to evaluate the symptoms of this item. The first score ranges from 0 points (no such symptoms) to 5 points (extremely severe Heavy); The second category is to assess the importance of this symptom to the patient, starting from 1 Points (not important) to 4 points (very important). Multiply these two fractions together to get the symptom-impact score , this is the individual evaluation score of each patient for each symptom.</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Herbal Interaction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants have no chronic respiratory disease or those who have been diagnosed as nasal&#xD;
        and sinusitis by a doctor, whose clinical diagnosis includes subjects with allergic&#xD;
        rhinitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 20, those who have no chronic respiratory disease or those who&#xD;
             have been diagnosed as nasal and sinusitis by a doctor, whose clinical diagnosis&#xD;
             includes subjects with allergic rhinitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient characteristics: age, gender, weight, education level, race, pregnancy and&#xD;
             breastfeeding status, smoking, drinking, caffeine, alcohol or drug poisoning, diet and&#xD;
             nutritional status, physical limitations, genetic history, etc. Exclude women under&#xD;
             the age of 20, unable to order their behavior, pregnant or breast-feeding women&#xD;
&#xD;
          2. Disease characteristics: Subjects who have been diagnosis of mental illness by&#xD;
             doctors, as well as long-term diarrhea or long-term use of Chinese medicine.&#xD;
&#xD;
          3. Environmental characteristics: other conditions that make patients unable to&#xD;
             cooperate. Such as unsuitability after screening, not signing the subject consent&#xD;
             form, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chang kaiwei, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>TaipeiVGH Center for Traditional Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang-Pey CHEN, professor</last_name>
    <phone>0228757453</phone>
    <phone_ext>333</phone_ext>
    <email>fpchen@vghtpe.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yen-Ying KUNG, doctor</last_name>
    <phone>0228757453</phone>
    <phone_ext>333</phone_ext>
    <email>yykung@vghtpe.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Traditional Medicine, Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yenying Kung, MD</last_name>
      <phone>886-2-28730502</phone>
      <email>yykung@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

